chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I had minor spots of psoriasis beginning 8 years ago.  Literally one or 2 small spots.  Around April of 2021 it started showing up on my legs.  By june it was all over my legs elbows and arms.   By the end of the year it was so bad i was wrapping my legs in saran wrap after putting lotion all over them.  It has killed my self esteem.  I cannot wear clothes i used to wear because if any of it shows i get asked omg what happened.   Or just people staring.  I itch everywhere all the time and it flakes off, has severe red raw skin, and is disgusting.   I can not look in the mirror anymore.    I am afraid it will now move to my face.    I have since learned that the covid vaccine has caused this.  I received my first vaccine in 3/2021 my second in April 2021 and received the booster jan 2022.   I went to a Dermotologist and she asked if i noticed a flare after my booster.   I had never put the 2 together.  At this point i am convinced it was the vaccine.  I am now having to be on a biologic and also experiencing joint issues.  They are sending me to Rheumatology for testing of psoriatic arthritis.    I am an otherwise healthy slim 56 year old woman.   I am absolutely devastated that no one indicated that this vaccine could cause issues with psoriasis sufferers.   I would have much more preferred to have gotten covid and built a natural immunity to that disease than have psoriasis all over my body which is now becoming psoriatic arthritis.  I am beyond upset at the lack of information on this.     I am a team player and wanted to be part of the pandemic solution. So didn?t think twice about getting vaccinated against covid.   Please don?t tell me it is better to have a skin condition and arthritis then to have gotten covid.  The risk of the above happening was 100% vs less than 1% of severe covid illness.
I administered a flucelvax vaccination IM into the 21 YOF's right arm. Immediately the patient rushed to the restroom with her mother as she felt nauseous. I went to the restroom area after approximately 2 minutes and witnessed the patient collapse numerous (3) times with one of the syncopal episodes resulting in her head hitting the concrete floor. During this time 911 was called and I went to go grab an epinephrine auto injector. The patient was sat up on the floor by her mother and was given orange juice to drink. There were no signs of anaphylaxis (breathing issues, bradycardia) so epinephrine was not administered. The paramedics arrived about 10 minutes after the administration of the vaccination and the patient's family elected to take her to the hospital personally as she was in stable condition.
Information has been received concerning a pt who on 01/12/99 was vaccinated with one dose of varicella vaccine. On 07/03/00 the pt developed visible lesions and on 07/05/00 had a full outbreak of chickenpox. The pt sought unspecified medical attention.
pt felt strange followed 5 min later by feeling short of breath and severe pain in head, mild wheezing auscultated
pt states she felt the vaccine entering into her body when she was getting the 1st dose Covid vaccine.  She developed massive chest pains within 30 minutes after getting the injection. She contacted her PCP and was told to go the ER, however she did not go.  These symptoms lasted about 45 minutes.  She started sweating profusely.  She then turned cold and started shaking violently.  She had fever, dizziness, coughing, SOB, tingling sensation in her fingers. These symptoms went away about 2 am next morning but after that these symptoms would return every night at 6:30.  She has been to hospital ER and was told she has riggers from getting the vaccine.  The day after her 2nd Covid dose she had a stroke.  After her booster shot she had suicidal thoughts and all of the other symptoms that she had after the 1st and 2nd dose.  She continues to have bouts of fever, SOB, fatigue, falling down, trouble breathing, chest pains, headaches, and brain fog.  She will be getting a heart monitor and continues medical treatment.
Was twitching, not as responsive as usual.  No fever or other symptoms.  No definite seizure.
The pt was given his first dose of Hep B vaccine at 2 days old. He was a premature child born at 37 weeks and a low birth weight of 4 lbs. 15 oz. The parents state almost "immediately" we could tell that he had vision problems and after a few months he had developmental delays. At less than 3 months old, the pt was given DPT, Polio and Hib. Within about 6 weeks, he developed small "jerks". The MD's office assured her it was probably nothing. Later these were diagnosed as myoclonic seizures. At 4 months he was unable to hold his head up, roll from tummy to back, push up on arms. At 5 months he received his second doses of the vaccines. Within 4 weeks, he started to have simple partial seizures along with the myoclonic seizures. A neurologist made the diagnoses and prescribed Phenobarbital. Several tests were ordered. At this time the childs growth slowed down as did his brain growth. He was diagnosed as microcep developmentally delayed epileptic and having static encephalopathy (later this was changed to unknown encephalopathy). An ophthalmologist states that the child eyes had developed correctly, but at 19 months the child had cataracts in both eyes and had surgery to remove them. The pertussis part of the vax was discontinued. The MD wanted the child to have a sleep apnea test scheduled for the night of 5/2/00. The child unexpectedly passed away that morning. Autopsy states  cause of death acute seizure activity due to chronic seizure disorder.
Hives and swelling with tenderness at the site of injection 24hrs after immunization administration. BENADRYL 2 tsp given x1.
Female patient reported no history of issues with vaccine. Arrived for administration of her second moderna dose, received it successfully. After about 10 minutes she asked for an additional bandaid, while I was wiping the blood off her arm and applying the new bandaid she said she wasn't feeling well, then fainted in her seat. I held her stable for about 15 seconds at which point she woke up and answered my questions which were: can you hear me? (yes) are you having any trouble breathing? (no) did you have something to eat this morning? (no). I provided the patient another chair to elevate her feet. I notified the other pharmacist on staff of the situation who stayed with the patient while I got a bag of chips and a soda for her. I asked her to stay a while longer until she's feeling well, then I went back to the pharmacy (while keeping the patient in view) to continue preparing and administering vaccines. The patient recovered well, laughing at herself and apologizing because she's never had this happen to her before. I assured her that no apology was necessary, I'm glad she's feeling better, and that she should stay as long as she needs. After about 15 more minutes the patient rose from her chair said that she felt fine and was going to leave to go get breakfast. I wished her well and allowed her to leave.
Breakthrough case.  Postivie for COVID on 09Nov2021; Breakthrough case.  Postivie for COVID on 09Nov2021; Dose received: 3; Dose received: 3; This is a spontaneous report from a contactable consumer (patient). A 49-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot Number: EW0217) via an unspecified route of administration, administered in arm left on 03Nov2021 (age at vaccination: 49-year-old) as dose 3 (booster), single and second dose bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot Number:EL3247) via an unspecified route of administration, administered in arm left on 16Feb2021 as dose 2, single and first dose bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot Number: EL3247) via an unspecified route of administration, administered in arm left on 26Jan2021 as dose 2, single all three doses taken for COVID-19 immunisation. Facility type vaccine was Workplace clinic. The patient took no other vaccine in four weeks, had no covid prior vaccination, was covid tested post vaccination, had no known allergies. There was no other medical history. The patient concomitant medications were not reported and no other medications in two weeks. On 08Nov2021, the patient experienced "Breakthrough case. Postivie for COVID on 09Nov2021". Adverse event resulted in Doctor or other healthcare Professional office/clinic visit. The patient underwent lab test and procedure which included PCR/ Nasal swab: Positive on 08Nov2021. No treatment was taken for adverse event. Outcome of event "Breakthrough case. Postivie for COVID on 09Nov2021" was recovering.
covid pneumonia; influenza a; Initial information received on 27-Dec-2022 regarding an unsolicited valid Social Media serious case received from a Consumer/Non-Health Care Professional.  This case involves an unknown age and unknown gender patient who experienced influenza A and covid pneumonia after receiving vaccine Influenza Vaccine.  The patient's past vaccination(s) included 2 shots of COVID-19 Vaccine. The patient's past medical history, medical treatment(s) and family history were not provided.   On an unknown date, the patient received a  dose of suspect Influenza Vaccine produced by unknown manufacturer (with dose, strength, formulation, expiry date, lot number not reported) via unknown route in unknown administration site for prophylaxis.  On an unknown date the patient developed serious events of Influenza A (Influenza) and COVID pneumonia (covid-19 pneumonia) (unknown latency) following the administration of Influenza Vaccine. The patient was hospitalized for these events.  No lab data was reported.  Action taken : Not Applicable.  It was not reported if the patient received a corrective treatment for both the events.   At time of reporting, the outcome was Unknown for both the events.   Seriousness Criteria: Hospitalization for both events and Medically Significant for covid-19 pneumonia.; Sender's Comments: Sanofi Company Comment dated 30-Dec-2022: This case involves an unknown age and unknown gender patient who experienced influenza A and covid pneumonia after receiving vaccine Influenza Vaccine. Based on the limited information provided, the causal role of the company suspect product cannot be excluded in occurrence of the events. However, lack of information regarding past and concomitant medication, any concurrent conditions, any family history precludes the comprehensive case assessment. Based upon the reported information, the role of the suspect vaccine cannot be assessed.
Patient experienced severe dizziness within 10 seconds of receiving vaccine. Patient was sitting down, about to drink water, and dropped the water bottle. He closed his eyes, remained sitting, drank small sips of water and gatorade and was responsive/answering questions. He lost color in his face which returned in about 10-15minutes. He reported that he was feeling better in 30 minutes. He stated he had a minor headache.
The influenza vaccine was administered first. The patient fainted within a few seconds after receiving Pfizer vaccine second. About a minute after fainting, the patient opened her eyes and it took several seconds for her to respond when her name was called. The nurse administering the vaccine reported that her pupils were both dilated. Patient knew immediately where she was when asked. She was a little shaky while resting in the chair. She was given a bottle of water and offered an cold compress as she reported being warm. She took the water but refused any cold compresses. She was able to move about fine after resting for about 5-10 minutes.
raisised EBV antibodies but no sxs; This case was reported by a pharmacist and described the occurrence of epstein-barr virus antibody positive in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, less than a year after receiving Shingrix, the patient experienced epstein-barr virus antibody positive. On an unknown date, the outcome of the epstein-barr virus antibody positive was unknown.   It was unknown if the reporter considered the epstein-barr virus antibody positive to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The shingrix dose caused raise in Epstein barr antibodies. The patient had raised Epstein-Barr Virus antibodies but no symptoms and had recent Shingrix. The reporter consented to follow up.
Tingling in his mouth that also affected his gums and teeth on the right of the face; Sluggishness; Severe pain, deep pain; Tingling in his mouth that also affected his gums and teeth on the right of the face; Tingling right of the face; Pain in the injection site; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 65-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 16-MAY-2023, the patient received the 1st dose of Shingrix (intramuscular, left deltoid). In MAY-2023, an unknown time after receiving Shingrix, the patient experienced injection site pain (Verbatim: Pain in the injection site). On 17-MAY-2023, the patient experienced tingling mouth (Verbatim: Tingling in his mouth that also affected his gums and teeth on the right of the face), sluggishness (Verbatim: Sluggishness), pain (Verbatim: Severe pain, deep pain), tingling teeth (Verbatim: Tingling in his mouth that also affected his gums and teeth on the right of the face) and tingling (Verbatim: Tingling right of the face). The patient was treated with paracetamol (Tylenol) and ibuprofen. The outcome of the injection site pain was not reported and the outcome of the tingling mouth, sluggishness, pain, tingling teeth and tingling were unknown.   It was unknown if the reporter considered the injection site pain, tingling mouth, sluggishness, pain, tingling teeth and tingling to be related to Shingrix.     It was unknown if the company considered the injection site pain, tingling mouth, sluggishness, pain, tingling teeth and tingling to be related to Shingrix.   Additional Information: GSK receipt date: 22-May-2023 This case was self reported by the patient.  The patient received first dose of Shingrix on and had sluggishness the day after vaccination.  The patient also described tingling in his mouth that also affected his gums and teeth on the right of the face affecting the lower jaw up to the right cheek bone. The patient described this tingling and severe pain, deep pain, as like being at a dentist getting a deep cleaning. The patient also stated that has had pain in the injection site.  The patient said he went to the dentist, had x-rays and nothing was found.  The patient also stated that he has been taking Tylenol and Ibuprofen for pain. The adverse event was filed.  The reporter consented to follow up.
Patient's mother states that 1 hour after the vaccine, child had itchy rash on face that self-resolved quickly. No medications were given. Parent informed me during a telephone call with me the day following the vaccine.
Swelling at injection sight, firm and hot to the touch; Swelling at injection sight, firm and hot to the touch; Swelling at injection sight, firm and hot to the touch; This is a spontaneous report from a contactable consumer, the patient. An 18-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 27Mar2021 at 08:30 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included alprazolam (MANUFACTURER UNKNOWN) and ethinylestradiol (MANUFACTURER UNKNOWN), both for an unknown indication from an unknown date and unknown if ongoing. On 28Mar2021, the patient experienced swelling at injection sight, firm and hot to the touch. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events swelling at injection sight, firm and hot to the touch was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
SUSPECTED CLINICAL VACCINE FAILURE; SUSPECTED COVID-19 INFECTION; This spontaneous report received from a patient via other manufacturer (Pfizer) concerned a 65 year old male. The patient's weight, height, and medical history were not reported. The patient experienced drug allergy when treated with naproxen. The patient received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin not reported, batch number: 1805031 expiry: unknown) dose was not reported, 1 total, first dose was administered on 01-APR-2021 10:00 on left arm for prophylactic vaccination. Age at time of vaccination 64 years old. The patient received non-company suspect vaccine included: elasomeran (moderna) (dose number in series 2) (form of admin, route of admin were not reported, batch number: 058E21A and expiry: unknown) dose was not reported, second dose was administered on 27-OCT-2021 13:00 on right arm for prophylactic vaccination;  The patient received non-company suspect vaccine included tozinameran (Pfizer/BioNTech) (dose number in series 3) (form of admin, route of admin were not reported, batch number: FM0698 and expiry: unknown) dose was not reported, third dose was administered on 03-APR-2022 19:00 on right arm for prophylactic vaccination. No concomitant medications were reported. On an unspecified date, the patient experienced suspected covid-19 (coronavirus disease) infection (dose number in series 3) and suspected clinical vaccine failure (dose number in series 1). The patient received non-company suspect drug paxlovid (form of admin, route of admin were not reported, batch number: unknown and expiry: unknown) dose was not reported, administered from 18-JUN-2022 to 23-JUN-2022 for covid-19 treatment. On 29-JUN-2022 07:00, the patient experienced covid rebound (positive antigen test within 5 days of completing paxlovid medication) (dose number in series 3). The action taken with covid-19 vaccine ad26.cov2.s, elasomeran, tozinameran was not applicable and with paxlovid was drug discontinued. The patient was recovering from suspected covid-19 infection, and the outcome of suspected clinical vaccine failure was not reported. This report was serious (Other Medically Important Condition). This report was associated with a product quality complaint: 90000241804.; Sender's Comments: V0-20220719674-Covid-19 Vaccine. Ad26.Cov2.s-Suspected clinical vaccination failure. The event(s) has an unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: SPECIAL SITUATIONS. Therefore, this event(s) is considered not related.
Headache after 3 hours of vaccination; headache with visual symptoms (aura) and pressure on the tight temporal vein on 4/11/21 and again on 4/12/21; and still having mild headache at this time ; relieved by taking Tylenol and caffeine
Persistent tingling/ partial numbness was noted town the left arm and left side of chest with warmth noted in the left hand and fingers, mild muscle soreness at the injection site
I have a fever it has reached 40, I can't smell or taste anything. More that a day has passed. Body pain.
Slightly raised rash noted by mother approximately 1 week after vaccine administered. Temp of 101 began on 02/01/20005 with rash on 02/03/05. noted spread to behind ears, forehead, chest and abdomen. Not vesicular in appearance. Mother contacted PMD probably post varivax vaccine.
Pain and weakness in arm (3 weeks now) and it is causing trouble sleeping and daily pain. The pain started the same day as the injection and has not been getting better over the past weeks, as reported by the patient.
HEADACHE, LIGHTHEADNESS, MYALGIAS, FEVER Narrative: LOW GRADE FEVER ONLY - ALL SYMPTOMS LASTER FOR 2 DAYS
Had cataract surgery in Mar2022 and before that in Aug2021; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An 81-year-old female patient received BNT162b2 (BNT162B2), on 25Mar2021 as dose 2, single (Lot number: EP7534) at the age of 81 years for covid-19 immunisation. The patient's relevant medical history included: "High blood pressure" (unspecified if ongoing), notes: She had high blood pressure and stuff like that. There were no concomitant medications. Vaccination history included: BNT162b2 (Dose 1, Single, Lot number- EL9269, Expiration Date- UNKNOWN), administration date: 04Mar2021, when the patient was 81-year-old, for COVID-19 Immunization. The following information was reported: CATARACT (medically significant) with onset Aug2021, outcome "unknown", described as "Had cataract surgery in Mar2022 and before that in Aug2021". Therapeutic measures were taken as a result of cataract. Patient called about the Pfizer BioNTech COVID-19 vaccine. She has had 4 doses of the COVID-19 Vaccine. 2 primary doses and 2 booster doses. She had high blood pressure and stuff like that, but nothing that was out of the ordinary for someone that was 82 years old. The information was captured as provided. She was told to get a booster dose. Vaccination Facility Type was reported as Satellite Clinic for the hospital. Prior Vaccinations within 4 weeks was reported as none. Patient had cataract surgery in Mar2022 and before that in Aug2021. Family Medical History Relevant to Adverse Events and relevant tests was reported as none. Other Conditions and investigations were reported as No.
it hurts enough to be distracting, making entire arm feel funny and hand week.; it hurts enough to be distracting, making entire arm feel funny and hand week.; it hurts enough to be distracting, making entire arm feel funny and hand week.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 61 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 30Apr2021 (Lot number: EW0171) at the age of 61 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, lot number: EW0158, route of administration: intramuscular, vaccine location: Left arm), administration date: 09Apr2021, when the patient was 61 years old, for Covid-19 immunization.  The following information was reported: PAIN IN EXTREMITY (non-serious), FEELING ABNORMAL (non-serious), MUSCULAR WEAKNESS (non-serious) all with onset 09May2021, outcome "recovered" (May2021) and all described as "it hurts enough to be distracting, making entire arm feel funny and hand week.". Therapeutic measures were not taken as a result of pain in extremity, feeling abnormal, muscular weakness.  Additional information: No arm pain right after vaccine, however, 9 days after vaccine dose 2, it hurts enough to be distracting, making entire arm feel funny and hand week. It was unknown, if covid prior vaccination. It was unknown, if covid tested post vaccination. The most recent COVID-19 vaccine was administered at facility. It was unknown, if patient receive any other vaccines within 4 weeks prior to the COVID vaccine.  No follow-up attempts are possible. No further information is expected.